Multiple sclerosis (MS) is an unpredictable disease of the central nervous system. It can affect vision, hearing, memory, balance and mobility. The majority of affected Canadians are between the ages of 15 and 40, and women are three times more likely to develop MS than men. Canada has one of the highest rates of MS in the world, and there is currently no cure.
In May, the Multiple Sclerosis Society of Canada is raising awareness about the experience of living with MS, and has organized a campaign called, “1 Day in May”. The campaign asks that you choose “1 Day in May” to donate your earnings to the MS Society so that, one day, there will be no MS. Donations will go towards MS research in Canada.
In support of Multiple Sclerosis Awareness Month, here is a list of relevant Cochrane Reviews:
- Rehabilitation for cognitive dysfunctions in persons suffering of Multiple Sclerosis (MS)
- Psychological treatments to help improve the quality of life of people with multiple sclerosis
- The use of the monoclonal antibody Natalizumab (NTZ) in patients with relapsing remitting multiple sclerosis (RRMS)
- The effects of the immunosuppressive drug azathioprine (AZA) widely used in multiple sclerosis (MS) before the treatments with interferons or glatiramer acetate
- Daclizumab (Zenapax) is an immunosuppressive drug, whose efficacy in patients with multiple sclerosis (MS) is worth of attention
